{"filing":{"accession_number":"0001193125-26-336057","cik":"0001845257","ticker":"LFST","company_name":"LifeStance Health Group, Inc.","form":"8-K","filing_date":"2026-08-06","report_date":"2026-08-06","primary_document":"lfst-20260806.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1845257/000119312526336057/lfst-20260806.htm"},"events":[{"id":25496,"run_id":23140,"accession_number":"0001193125-26-336057","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.97,"summary":"LifeStance issued a press release on August 6, 2026 announcing Q2 2026 financial results, including revenue of $435.4 million (26% YoY growth), net income of $23.6 million (vs. prior-year loss of $3.8 million), and Adjusted EBITDA of $66.0 million, along with raised full-year 2026 guidance.","company_name":"LifeStance Health Group, Inc.","ticker":"LFST","filing_date":"2026-08-06","form":"8-K","submitted_at":null,"items":[{"id":26337,"accession_number":"0001193125-26-336057","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"reasoning":"LifeStance issued a press release on August 6, 2026 announcing Q2 2026 financial results, including revenue of $435.4 million (26% YoY growth), net income of $23.6 million (vs. prior-year loss of $3.8 million), and Adjusted EBITDA of $66.0 million. The filing explicitly states under Item 2.02 that the company \"issued a press release announcing its results of operations for the second quarter ended June 30, 2026,\" with the press release furnished as Exhibit 99.1. This is a standard quarterly earnings disclosure material to investors.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-08T02:49:27.355576+00:00","company_name":"","ticker":null,"filing_date":""},{"id":26338,"accession_number":"0001193125-26-336057","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"The Item 7.01 disclosure furnishes a press release announcing LifeStance's Q2 2026 financial results, including revenue of $435.4 million (26% YoY growth), net income of $23.6 million (vs. prior-year loss of $3.8 million), and Adjusted EBITDA of $66.0 million. The filing also raises full-year 2026 guidance and announces a $100 million share repurchase program. This is a classic earnings release disclosure with comprehensive financial highlights and forward guidance.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-08T02:49:27.355576+00:00","company_name":"","ticker":null,"filing_date":""}]},{"id":25497,"run_id":23140,"accession_number":"0001193125-26-336057","anchor_item_number":"8.01","event_type":"dividend_distribution","event_domain":"financial","is_material":true,"confidence":0.92,"summary":"The Board of Directors approved a $100 million share repurchase program on August 5, 2026, replacing a prior $100 million program, representing a significant capital return to shareholders.","company_name":"LifeStance Health Group, Inc.","ticker":"LFST","filing_date":"2026-08-06","form":"8-K","submitted_at":null,"items":[{"id":26339,"accession_number":"0001193125-26-336057","item_number":"8.01","item_title":"Other Events.","event_type":"dividend_distribution","event_domain":"financial","is_material":true,"confidence":0.92,"reasoning":"The Board of Directors approved a $100 million share repurchase program on August 5, 2026, replacing a prior $100 million program. Share repurchases are a form of capital return to shareholders and fall under the dividend_distribution category, which encompasses \"share-repurchase programs.\" The program is material as it represents a significant capital allocation decision affecting shareholder value and is disclosed prominently in the earnings release.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-08T02:49:27.355576+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":26337,"accession_number":"0001193125-26-336057","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"reasoning":"LifeStance issued a press release on August 6, 2026 announcing Q2 2026 financial results, including revenue of $435.4 million (26% YoY growth), net income of $23.6 million (vs. prior-year loss of $3.8 million), and Adjusted EBITDA of $66.0 million. The filing explicitly states under Item 2.02 that the company \"issued a press release announcing its results of operations for the second quarter ended June 30, 2026,\" with the press release furnished as Exhibit 99.1. This is a standard quarterly earnings disclosure material to investors.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-08T02:49:27.355576+00:00","company_name":"LifeStance Health Group, Inc.","ticker":"LFST","filing_date":"2026-08-06"},{"id":26338,"accession_number":"0001193125-26-336057","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"The Item 7.01 disclosure furnishes a press release announcing LifeStance's Q2 2026 financial results, including revenue of $435.4 million (26% YoY growth), net income of $23.6 million (vs. prior-year loss of $3.8 million), and Adjusted EBITDA of $66.0 million. The filing also raises full-year 2026 guidance and announces a $100 million share repurchase program. This is a classic earnings release disclosure with comprehensive financial highlights and forward guidance.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-08T02:49:27.355576+00:00","company_name":"LifeStance Health Group, Inc.","ticker":"LFST","filing_date":"2026-08-06"},{"id":26339,"accession_number":"0001193125-26-336057","item_number":"8.01","item_title":"Other Events.","event_type":"dividend_distribution","event_domain":"financial","is_material":true,"confidence":0.92,"reasoning":"The Board of Directors approved a $100 million share repurchase program on August 5, 2026, replacing a prior $100 million program. Share repurchases are a form of capital return to shareholders and fall under the dividend_distribution category, which encompasses \"share-repurchase programs.\" The program is material as it represents a significant capital allocation decision affecting shareholder value and is disclosed prominently in the earnings release.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-08T02:49:27.355576+00:00","company_name":"LifeStance Health Group, Inc.","ticker":"LFST","filing_date":"2026-08-06"}]}